Haemonetics stock slides 7% as revenue dip and hospital softness blunt raised outlook
Haemonetics shares dropped 7% Friday to $60.46 despite the company raising its full-year profit and cash flow outlook. Third-quarter revenue fell 2.7% to $339 million, while adjusted EPS rose to $1.31. Interventional technology revenue declined 12%, offsetting a 3% gain in plasma. Citigroup cut its price target to $75.
